Platinum Complexes And Their Anti-Tumour Activity Against Chronic Lymphocytic Leukaemia Cells

1. Jakupec MA, Galanski M, Arion VB, Hartinger CG & Keppler BK. (2008). Antitumor metal compounds: more than theme and variations. Dalton Trans. 14;(2), 183-194.10.1039/B712656P18097483Search in Google Scholar

2. Florea A & Büsselberg D. (2001). Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. 15;3(1), 1351-1371.10.3390/cancers3011351375641724212665Search in Google Scholar

3. Oun R. & Wheate NJ. (2013). Platinum Anticancer Drugs. In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1710-1714). New York, Heidelberg, Dordrecht, London:Springer.Search in Google Scholar

4. Arnesano F. (2013). Platinum Complexes and Methionine Motif in Copper Transport Proteins Interaction In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1714-1723). New York, Heidelberg, Dordrecht, London:Springer.Search in Google Scholar

5. Kostova I. (2006). Platinum Complexes as Anticancer Agents. Recent Pat Anticancer Drug Discov. 1(1), 1-22.10.2174/15748920677524645818221023Search in Google Scholar

6. Swerdlow SH, Campo E, Haris NL, Jaffe ES, Poleri SA, Stein H, Thiele J & Vardiman JW. (2008). WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. (4th ed.) (pp 180-184). Lyon: International Agency for Research on Cancer.Search in Google Scholar

7. Aster JC. (1999). Diseases of white blood cells, lymph nodes, spleen, and thymus In: Kumar V, Abbas AK & Fausto N. Robbins and Cotran, Pathologic basis of disease (7th ed.) (pp 661-709). Philadelphia: Elsevier Saunders.Search in Google Scholar

8. Nahi H, Lehman S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C & Merup M. (2004). Effects oh PRIMA-1 on chronic lymphocytis leukaemia cells with and without hemizygous p53 deletion. Br J Haematol. 127(3), 285-291.10.1111/j.1365-2141.2004.05210.x15491287Search in Google Scholar

9. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson Bruce, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ & Rai K. (2006). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 107(3), 859-861.10.1182/blood-2005-04-167716223776Search in Google Scholar

10. Chastain EC & Duncavage EJ. (2015). Clinical Prognostic Biomarkers in Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma. Arch Pathol Lab Med. 139(5), 602-607.10.5858/arpa.2014-0086-RA25248094Search in Google Scholar

11. Caligaris-Cappio F. (2009). Chronic lymphocytic leukemia: “Cinderella” is becoming a star. Mol Med. 15(3-4), 67-69.10.2119/molmed.2008.00126260049719081769Search in Google Scholar

12. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN & Pasternack BS. (1975). Clinical staging of chronic lymphocytic leukemia. Blood. 46, 219-234.10.1182/blood.V46.2.219.219Search in Google Scholar

13. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S & Gremy F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48: 198-206.Search in Google Scholar

14. Vujić JM, Kaluđerović GN, Zmejkoviski BB, Milovanović M, Volarević V, Arsenijević N, Stanojković TP & Trifunović S. (2012). Stereospecific ligands and their complexes: Part X: Syntesis, characterization and in vitro antitumoral activity of platinum (IV) complexes with O,O′-dialkyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl) pentanoate ligands. Inorganica Chimica Acta. 390, 123-128.10.1016/j.ica.2012.03.048Search in Google Scholar

15. Habashi F. (2013) Platinum, Physical and Chemical Properties In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1741-1742). New York, Heidelberg, Dordrecht, London:Springer.10.1007/978-1-4614-1533-6_422Search in Google Scholar

16. Palm-Espling ME & Wittung-Stafshede P. (2013) Platinum Interaction with Copper Proteins. In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1723-1729). New York, Heidelberg, Dordrecht, London:Springer.10.1007/978-1-4614-1533-6_534Search in Google Scholar

17. Arsenijević M, Milovanović M, Volarević V, Čanović D, Arsenijević N, Soldatović T, Jovanović S & Bugarčić ŽD. (2012). Cytotoxic properties of platinum(IV) and dinuclear platinum (II) complexes and their ligand substitution reactions with guanosine-5′-monophosphate. Transition Metal Chemistry. 37: 481-488.Search in Google Scholar

18. Vujić JM, Kaluđerović GN, Milovanović M, Zmejkoviski BB, Volarević V, Živić D, Đurđević P, Arsenijević N & Trifunović S. (2011). Stereospecific ligands and their complexes: Part VII Syntesis, characterization and in vitro antitumoral activity of platinum(II) complexes with O,O′-dialkyl esters of (S,S)-ethylenediamine-N,N′-di-2-(4-methyl) pentanoic acid. Eur J Med Chem. 46(9), 4559-4565.10.1016/j.ejmech.2011.07.03421840630Search in Google Scholar

19. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C & Peres JM. (2007). Biochemical Mechanisms of Cisplatin Cytotoxicity. Anticancer Agents Med Chem. 7(1), 3-18.10.2174/18715200777931404417266502Search in Google Scholar

20. Gately DP & Howel SB. (1993). Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer. 67(6), 1171-1176.10.1038/bjc.1993.22119685228512802Search in Google Scholar

21. Bordin DL, Lima M, Lenz G, Saffi J, Meira LB, Paul Mésange P, Soares DH, Larsen AK, Escargueil AE & Henriques JAP. (2013). DNA alkylation damage and autophagy induction. Mutat Res. 753(2), 91-99.10.1016/j.mrrev.2013.07.00123872363Search in Google Scholar

22. Blair BG, Larson CA & Howell SB. (2009). Copper-Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 15(13), 4312-4321.10.1158/1078-0432.CCR-09-0311286264019509135Search in Google Scholar

23. Silaghi-Dumitrescu R & Bischin C. (2013). Platinum-Containing Anticancer Drugs and Proteins, Interaction In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1742-1748). New York, Heidelberg, Dordrecht, London: Springer.Search in Google Scholar

24. Kampfenkel K, Kushnir S, Babiychuk E, Inze` D & Van Montagu M. (1995). Molecular Characterization of a Putative Arabidopsis thaliana Copper Transporter and Its Yeast Homologue. J Biol Chem. 270(47), 28479-28486.10.1074/jbc.270.47.284797499355Search in Google Scholar

25. Eckstein N & Hass B. (2013). Platinum-Resistant Cancer In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1748-1751). New York, Heidelberg, Dordrecht, London: Springer.Search in Google Scholar

26. Boulikas T, Pantos A, Bellis E & Christofis P. (2007). Designing platinum compounds in cancer: structures and mechanism. Cancer Therapy. 5, 537-583.Search in Google Scholar

27. Gonzales VM, Fuertes MA, Alonso C & Perez JM. (2001). Is Cisplatin-Induced Cell Death Always Produced by Apoptosis? Mol Pharmacol. 59(4), 657-63.Search in Google Scholar

28. Ashkenazi A & Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. The Journal of Clinical Investigation 2008; 118(8): 1979-1990.Search in Google Scholar

29. Del Bello B, Valentini MA, Yunino F, Comporti M & Maellaro E. (2001). Cleavage of Bcl-2 and cisplatin-induced apoptosis of human melanoma cells. Onkogene. 20(33), 4591-4595.10.1038/sj.onc.120461811494156Search in Google Scholar

30. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M & Krammer PH. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 188(11), 2033–2045.10.1084/jem.188.11.203322123869841917Search in Google Scholar

31. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res.11(17), 6100-6102.10.1158/1078-0432.CCR-05-108316144907Search in Google Scholar

32. Alderden AA, Hall M D. & Hambley TW. (2006). The discovery and Development of Cisplatin. J Chem Educ. 83(5), 728-734.10.1021/ed083p728Search in Google Scholar

33. Bou Samra E, Klein B, Commes T & Moreaux J. (2014). Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. Biomed Res Int. 2014, 423174.10.1155/2014/423174402684924883311Search in Google Scholar

34. Tonino SH, van Gelder M, Eldering E, van Oers MH & Kater AP. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia. 24(3), 652-654.10.1038/leu.2009.24019956201Search in Google Scholar

35. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E & Kater AP. (2011). ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene. 30(6), 701-713.10.1038/onc.2010.441399540920935673Search in Google Scholar

36. Zecevic A, Sampath D, Ewald B, Chen R, Wierda W & Plunkett W. (2011). Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin Cancer Res. 17(14), 4731-4741.10.1158/1078-0432.CCR-10-2561553434221632856Search in Google Scholar